Basis of Presentation and Significant Accounting Policies - Narrative (Details)					1 Months Ended					3 Months Ended			9 Months Ended		12 Months Ended
	Aug. 19, 2024 USD ($)	Jul. 17, 2024	Mar. 09, 2024 USD ($)	Jan. 29, 2024 USD ($)	Mar. 31, 2023 USD ($)	Dec. 31, 2019 USD ($)	Oct. 31, 2017 USD ($)	May 31, 2017 USD ($)	Jun. 30, 2016 USD ($)	Sep. 30, 2024 USD ($)	Mar. 31, 2024 USD ($)	Sep. 30, 2023 USD ($)	Sep. 30, 2024 USD ($) segment	Sep. 30, 2023 USD ($)	Dec. 31, 2023 USD ($)	Jul. 30, 2024 USD ($)	Apr. 30, 2023 USD ($)	Oct. 31, 2018	Sep. 30, 2018
Reverse stock split conversion ratio		0.005
Accumulated deficit										$ 277,777,368			$ 277,777,368		$ 254,370,827
Net loss from continuing operations										(10,545,752)		$ (11,206,263)	(24,487,149)	$ (35,255,457)
Issuance of common stock from public offering	$ 13,100,000		$ 1,200,000										22,001,799
Cash, cash equivalents and short term investments										4,800,000			$ 4,800,000
Substantial doubt about going concern within one year													true
Loss on debt extinguishment										730,000			$ 560,000
Revenue										922,365		723,126	5,196,257	2,146,804
Deferred revenue										2,300,000			2,300,000
Inventory impairment expense										0		$ 0	0	$ 0
Land option agreements										$ 200,000			$ 200,000
Number of operating segments | segment													1
Shattuck
License fee received									$ 50,000.00
Proceeds from milestone payment					$ 100,000
Shattuck | Kopfkino IP, LLC
Consideration				$ 1,000,000.0
Other income											$ 1,000,000.0
Maximum
Estimated useful lives										8 years			8 years
Grant and contract revenue
Amount awarded from CPRIT grant													$ 200,000
Lab equipment
Estimated useful lives										5 years			5 years
Computers
Estimated useful lives										3 years			3 years
Furniture and fixtures and vehicles
Estimated useful lives										8 years			8 years
New Note
Interest rate																1.00%
Principal amount																$ 750,000
Cash payment to be made to the Company																$ 2,500,000
Loss on debt extinguishment										$ 730,000			$ 730,000
Pelican Therapeutics, Inc.
Ownership interest in subsidiary										85.00%			85.00%		85.00%			85.00%	80.00%
Scorpius Therapeutics, Inc.
Ownership interest in subsidiary										94.00%			94.00%
Pelican Therapeutics, Inc. | Grant and contract revenue
Amount awarded from CPRIT grant															$ 15,200,000
Remaining grant amount receivable																	$ 1,500,000
Pelican Therapeutics, Inc. | Grant and contract revenue | Tranche 1
Revenue								$ 1,800,000
Pelican Therapeutics, Inc. | Grant and contract revenue | Tranche 2
Revenue							$ 6,500,000
Pelican Therapeutics, Inc. | Grant and contract revenue | Tranche 3
Revenue						$ 5,400,000
Pelican Therapeutics, Inc. | Grant and contract revenue | Maximum
Amount awarded from CPRIT grant									$ 15,200,000